shadow_tr
Institutional Biosafety Committee

 

Policy on the Use of Recombinant DNA

 

Research involving recombinant DNA conducted at or sponsored by Tulane University, or research conducted by Tulane University faculty members or students, must be conducted in a manner that does not pose a significant risk to the health or safety of laboratory workers, others in the Institution, the public, or the environment. Federal law on use of recombinant DNA mandates the establishment of the IBC, which reviews, approves and oversees projects involving recombinant DNA.

A. All NIH-funded projects involving recombinant DNA techniques must comply with the NIH Guidelines. Non-compliance may result in (i) suspension, limitation, or termination of financial assistance for the noncompliant NIH-funded research project and of NIH funds for recombinant DNA research at the Institution, or (ii) a requirement for prior NIH approval of any or all recombinant DNA projects at the Institution.

B. All non-NIH funded projects involving recombinant DNA techniques conducted at or sponsored by the Institution must comply with the NIH Guidelines. Noncompliance may result in (i) suspension, limitation, or termination of NIH funds for recombinant DNA research at the Institution, or (ii) a requirement for prior NIH approval of any or all recombinant DNA projects at the Institution.

 


 



 

Office of Biosafety, Tulane University, New Orleans, LA 70112 504-988-0300 ibc@tulane.edu